文献速递淋巴瘤白血病

Wnt5a通过ROR1/DOCK2依赖机制增强慢性淋巴细胞白血病增殖及ERK1/2磷酸化

Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
PubMed 文献 · Leukemia · 2020-10-23

慢性淋巴细胞白血病(CLL)患者血浆Wnt5a水平高,Wnt5a可诱导ERK1/2磷酸化并增强CLL细胞增殖。该效应可被ERK1/2抑制剂、ERK1/2特异性siRNA或抗ROR1单抗cirmtuzumab抑制。机制研究显示Wnt5a通过ROR1/DOCK2依赖通路激活ERK1/2,且该通路不依赖BTK,伊布替尼不能抑制Wnt5a诱导的ERK1/2或DOCK2磷酸化。

要点

  • Wnt5a通过ROR1/DOCK2依赖通路诱导ERK1/2磷酸化并增强CLL细胞增殖。
  • 该效应可被ERK1/2抑制剂、ERK1/2 siRNA或cirmtuzumab抑制。
  • 伊布替尼不能抑制Wnt5a诱导的ROR1依赖ERK1/2或DOCK2磷酸化。

核心结论

  • Wnt5a通过ROR1/DOCK2依赖通路激活ERK1/2并增强CLL细胞增殖,该通路独立于BTK。

研究设计与样本

  • 研究使用CLL患者细胞及CLL衍生细胞系MEC1进行体外机制研究。
  • 构建ROR1表达、ROR1ΔPRD缺失及ROR1P808A突变的MEC1细胞,并用siRNA沉默DOCK2或ERK1/2。

主要发现

  • CLL患者血浆Wnt5a水平高,Wnt5a可诱导ERK1/2磷酸化并增强CLL细胞增殖。
  • 表达ROR1的MEC1-ROR1细胞磷酸化ERK1/2水平高于亲本MEC1、ROR1ΔPRD或ROR1P808A转染细胞。
  • siRNA沉默DOCK2可抑制Wnt5a诱导MEC1-ROR1或CLL细胞中ERK1/2磷酸化。
  • 表达ROR1的CLL细胞磷酸化ERK1/2或DOCK2水平高于不表达ROR1的CLL细胞。
  • 伊布替尼可抑制B细胞受体连接诱导的ERK1/2和DOCK2磷酸化,但不能抑制Wnt5a诱导的ROR1依赖ERK1/2或DOCK2磷酸化。

临床怎么用

  • Wnt5a/ROR1/DOCK2/ERK1/2通路可能为CLL提供独立于BTK的治疗靶点。
  • 抗ROR1单抗cirmtuzumab或ERK1/2抑制剂可能干预Wnt5a诱导的CLL细胞增殖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphocytic leukemia (CLL) have high plasma-levels of Wnt5a, which can induce phosphorylation of ERK1/2 and enhance CLL-cell proliferation. Such effects could be inhibited by treatment with an ERK1/2 inhibitor, ERK1/2-specific siRNA, or cirmtuzumab, an anti-ROR1 mAb. The CLL-derived line, MEC1, expresses Wnt5a, but not ROR1. MEC1 cells transfected to express ROR1 (MEC1-ROR1) had higher levels of phosphorylated ERK1/2 than parental MEC1, or MEC1 transfected with ROR1ΔPRD, a truncated ROR1 lacking the cytoplasmic proline-rich domain (PRD), or ROR1P808A a mutant ROR1 with a P→A substitution at 808, which is required for complexing with the Rac-specific-guanine-nucleotide-exchange factor DOCK2 upon stimulation with Wnt5a. We silenced DOCK2 with siRNA and found this repressed the capacity of Wnt5a to induce ERK1/2 phosphorylation in MEC1-ROR1 or CLL cells. CLL cells that expressed ROR1 had higher levels of phosphorylated ERK1/2 or DOCK2 than CLL cells lacking ROR1. Although we found ibrutinib could inhibit the phosphorylation of ERK1/2 and DOCK2 induced by B-cell-receptor ligation, we found that this drug was unable to inhibit Wnt5a-induced, ROR1-dependent phosphorylation of ERK1/2 or DOCK2. This study demonstrates that Wnt5a can induce activation of ERK1/2 and enhance CLL-cell proliferation via a ROR1/DOCK2-dependent pathway independent of BTK.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hasan MK, Ghia EM, Rassenti LZ, et al. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia. 2020. PMID: 33097837. doi:10.1038/s41375-020-01055-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。